Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.

The deficiency in available targeted agents and frequency of chemoresistance are primary challenges in clinical management of triple-negative breast cancer (TNBC). The aberrant expression of USP21 and JAK2 represents a characterized mechanism of TNBC progression and resistance to paclitaxel (PTX). Despite its clear that high expression of USP21-mediated de-ubiquitination leads to increased levels of JAK2 protein, we lack regulator molecules to dissect the mechanisms that the interaction between USP21 and JAK2 contributes to the phenotype and resistance of TNBC. Here, we report a USP21/JAK2/STAT3 axis-targeting regulator 13c featuring a N -anthraniloyl tryptamine scaffold that showed excellent anti -TNBC potency and promising safety profile. Importantly, the therapeutic potential of using 13c in combination with PTX in PTX -resistant TNBC was demonstrated. This study showcases N -anthraniloyl tryptamine derivatives as a novel anti -TNBC chemotype with a pharmacological mode of action targeting the USP21/JAK2/STAT3 axis and provides a potential therapeutic target for the treatment of TNBC. [Display omitted] • The anti -TNBC potency of N -anthraniloyl tryptamine scaffold was well-identified. • Compound 13c showed excellent potency against MDA-MB-231 and HCC-1806 cell lines. • Compound 13c showed potential capability to regulate USP21/JAK2/STAT3 axis. • Compound 13c showed significant anti -TNBC efficacy in vivo. [ABSTRACT FROM AUTHOR]